Michal Eid

ORCID: 0000-0002-4433-5326
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Gastrointestinal Tumor Research and Treatment
  • Neuroendocrine Tumor Research Advances
  • Cancer Genomics and Diagnostics
  • Colorectal and Anal Carcinomas
  • Pancreatitis Pathology and Treatment
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Surgical Treatments
  • Renal cell carcinoma treatment
  • Gastrointestinal disorders and treatments
  • Metastasis and carcinoma case studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Multiple and Secondary Primary Cancers
  • Cancer Diagnosis and Treatment
  • Education, Psychology, and Social Research
  • Colorectal Cancer Treatments and Studies
  • Vascular Anomalies and Treatments
  • Bladder and Urothelial Cancer Treatments
  • IgG4-Related and Inflammatory Diseases
  • Tracheal and airway disorders
  • Genetic factors in colorectal cancer
  • Cancer Immunotherapy and Biomarkers
  • Viral-associated cancers and disorders
  • Lymphoma Diagnosis and Treatment
  • Soft tissue tumor case studies

Masaryk University
2018-2025

University Hospital Brno
2018-2024

Dartmouth–Hitchcock Medical Center
2022-2023

Dartmouth College
2023

Nasser Institute hospital
2023

Zbrojovka Vsetín (Czechia)
2021

Ocní klinika
2019-2020

Biliary drainage is then one of the necessary procedures to help patients suffering from icterus reduce serum bilirubin levels and relieve symptoms. The aim this study was identifying risk factors for survival in with cholangiocarcinoma (CCA) treated percutaneous transhepatic biliary (PTBD) develop a simple scoring system predicting PTBD insertion. This single-centre retrospective included 175 consecutive undergoing extrahepatic CCA (perihilar distal). Prognostic affecting were analysed. A...

10.1038/s41598-025-86443-8 article EN cc-by Scientific Reports 2025-01-16

693 Background: Platinum-based chemotherapy followed by avelumab 1L maintenance treatment for patients with nonprogressive disease is a standard of care in la/mUC. In the Czech Republic, following EU approval, there requirement to provide real-world data “highly innovative medicinal products” and obtaining reimbursement requires registry creation collection. Interim results from retrospective analysis national Republic were reported previously; here, we report longer-term results. Methods:...

10.1200/jco.2025.43.5_suppl.693 article EN Journal of Clinical Oncology 2025-02-10

Significant changes have recently occurred in the treatment of locally advanced rectal cancer. These include a complete administration systemic therapy neoadjuvant phase treatment, nonsurgical interventions case clinically response and using immunotherapy patients with deficiency ofmismatch repair. Although there is no universally accepted standard, concept total therapy, non-operative management widely clinical practice. The care cancer multimodal, comprehensive should be based on...

10.48095/ccrvch2025105 article EN Perspectives in Surgery 2025-03-31

557 Background: Avelumab 1LM treatment is recommended by international guidelines as the standard of care for pts with la/mUC that has not progressed 1L platinum-based chemotherapy (PBC) and been approved in EU since Jan 2021. In Czech Republic, following approval, there a requirement to provide real-world data “highly innovative medicinal products” such avelumab when reimbursement decisions are temporary. Obtaining therefore requires creation registry collect data. We report interim results...

10.1200/jco.2024.42.4_suppl.557 article EN Journal of Clinical Oncology 2024-01-29

Neurofibromatosis type-1 (NF1), also called von Recklinghausen disease, is a rare genetic disease which can lead to the development of benign or even malignant tumors. NF1 mostly diagnosed in children early adolescents who present with clinical symptoms. A curative therapy still missing and management based on careful surveillance. Concerning tumors affect gastrointestinal tract patients NF1, most common stromal tumor (GIST).

10.1186/s13000-019-0848-7 article EN cc-by Diagnostic Pathology 2019-07-13

Pancreatic ductal adenocarcinoma (PDAC) is now the 11th most common cancer and in 2018 there were 458,918 new cases worldwide.In Czech Republic, a total of 2,173 patients diagnosed 2015, ranking second incidence contrast to other malignancies, recent research has not brought any major breakthrough treatment PDAC hence prognosis remains very serious.Radical resection only curative approach, but after initiation standard pathological evaluation resected tissue, according Leeds protocol, 80%...

10.4149/neo_2020_200408n372 article EN Neoplasma 2020-09-03

Pancreatic carcinoma is an aggressive tumor with a grim prognosis.Accurate staging essential for indicating surgery in patients borderline resectable tumors.This paper examines the correlation between pre-operation characteristics of tumors found on CT, infiltration individual resection margins as confirmed by pathologist, and survival pancreatic head ductal adenocarcinoma.This prospective cohort study involved operated adenocarcinoma, which was clearly based CT intraoperative observation...

10.4149/neo_2020_190923n955 article EN Neoplasma 2020-07-01

Introduction: The aim of the study was to perform a retrospective analysis patients who had undergone laparoscopic resection for pancreatic cancer (PC) at Department Surgery Faculty Medicine, Masaryk University and Hospital Brno, Czech Republic from 2010 2023. Methods: Forty-six with (n=19) or open (n=27) distal pancreatectomy (DP) PC were included. Both groups statistically evaluated compared in following parameters: clinical stage, tumor grade, nodes examined by pathologist, blood loss,...

10.33699/pis.2024.103.4.122-131 article EN Perspectives in Surgery 2024-04-15

Imunoglubulin G4 asociované nemoci tvoří skupinu chorob, které charakterizuje vysoká hladina imunoglobulinu (IgG4) v krevním séru, zvýšený obsah lymfocytů a plasmatických buněk s IgG4 parenchymu některých orgánů storiformní fibróza. Nejčastěji postiženým orgánem je pankreas. Hovoříme o autoimunitní formě pankreatitidy, která se rozlišuje na dva typy. 1. typ vysokým obsahem pankreatickém významně častější než 2. má zásadní odlišnost, i pokud jde přítomnost extrapankreatických postižení. V...

10.36290/vnl.2021.011 article CS Vnitřní lékařství 2021-03-02

Abstract Multidisciplinary molecular tumor boards (MTB) are already well established in many comprehensive cancer centers and play an important role the individual treatment planning for patients. Comprehensive genomic profiling of tissue based on next-generation sequencing is currently performed diagnostic mainly predictive testing. If somatic variants identified, which suspected to be pathogenic germline (PGVs), MTB propose genetic counseling DNA Commonly used approaches do not include a...

10.1093/mutage/geae014 article EN cc-by Mutagenesis 2024-05-22

Ampularni adenokarcinom (AA) je relativně vzacne onemocněni, tvořici meně něž 1 % vsech nadorů gastrointestinalniho traktu, ackoli to druha nejcastějsi malignita periampularni oblasti (po karcinomu pankreatu). Mezi možnosti lecby ampularnich neoplazii patři endoskopicka resekce, transduodenalni chirurgicka ampulektomie nebo hemipankreatoduodenektomie. V době diagnozy onemocněni u AA vyssi pravděpodobnost kurabilni chirurgicke resekce než pankreatu (80 vs. 20 %) a rovněž 5lete přeživani...

10.14735/amgh2018401 article CS Gastroenterologie a hepatologie 2018-10-31
Coming Soon ...